Nefrite lupica, pubblicazione su "Nature Medicine" del team del prof. Roccatello
Il Centro Universitario di Eccellenza per le Malattie Rare Reumatologiche, Nefrologiche e Rare dell'Ospedale Hub San Giovanni Bosco (ASL Città di Torino) ha recentemente consegnato alla letteratura scientifica internazionale, sulla rivista "Nature Medicine" la propria esperienza sul trattamento dei casi di lupus più severi, resistenti ai trattamenti convenzionali e innovativi.
Di seguito l'abstract dell'articolo:
«Treatment-refractory lupus nephritis (LN) has a high risk of a poor outcome and is often life-threatening. Here we report a case series of six patients (one male and five females) with a median age of 41.3 years (range, 20–61 years) with refractory LN who received renal biopsies and were subsequently treated with intravenous daratumumab, an anti-CD38 monoclonal antibody (weekly for 8 weeks, followed by eight biweekly infusions and up to eight monthly infusions). One patient did not show any improvement after 6 months of therapy, and daratumumab was discontinued. In five patients, the mean disease activity, as assessed by the Systemic Lupus Erythematosus Disease Activity 2000 index, decreased from 10.8 before treatment to 3.6 at 12 months after treatment. Mean proteinuria (5.6 g per 24 h to 0.8 g per 24 h) and mean serum creatinine (2.3 mg dl−1 to 1.5 mg dl−1) also decreased after 12 months. Improvement of clinical symptoms was accompanied by seroconversion of anti-double-stranded DNA antibodies; decreases in median interferon-gamma levels, B cell maturation antigen and soluble CD163 levels; and increases in C4 and interleukin-10 levels. These data suggest that daratumumab monotherapy warrants further exploration as a potential treatment for refractory LN».